In vivo dose response relation of inhaled fluticasone propionate (FP), adults with bronchial asthma

N. A. Jatoi, M. N. Jatoi, J. P. Cullen, S. J. Lane (Dublin, Ireland)

Source: Annual Congress 2004 - Therapy in asthma and COPD
Session: Therapy in asthma and COPD
Session type: Thematic Poster Session
Number: 889
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
N. A. Jatoi, M. N. Jatoi, J. P. Cullen, S. J. Lane (Dublin, Ireland). In vivo dose response relation of inhaled fluticasone propionate (FP), adults with bronchial asthma. Eur Respir J 2004; 24: Suppl. 48, 889

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Effect of addition of salmeterol vs doubling the dose of fluticasone propionate on specific airway resistance in children with asthma
Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma
Year: 2008


Airway hyperresponsiveness and treatment effectiveness during a one year study of the combination of salmeterol and fluticasone propionate (FP) compared with FP and salmeterol alone in mild to moderate asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 386s
Year: 2002

Systemic exposure and topical efficacy for inhaled fluticasone propionate (FP) in asthmatics
Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II
Year: 2010

Salmeterol/fluticasone propionate combination (SFC) versus doubling dose of fluticasone propionate (FP) in children with asthma insufficiently controlled on moderate doses of inhaled corticosteroids
Source: Annual Congress 2010 - Managing asthma and allergic disease in children
Year: 2010


Effect of switching from high dose fluticasone propionate (FP) to FP/salmeterol (FSC) on airway inflammation in asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 44s
Year: 2004

Control of airway inflammation is maintained in asthma patients following a 60% reduction in ICS dose with fluticasone propionate/salmeterol (FSC) compared with higher dose fluticasone propionate (FP) alone
Source: Eur Respir J 2004; 24: Suppl. 48, 308s
Year: 2004

The acute protective effect of a single dose of fluticasone propionate (FP) on the allergen-induced early asthmatic response in man
Source: Eur Respir J 2002; 20: Suppl. 38, 308s
Year: 2002

Late Breaking Abstract - Dose responses for topical efficacy and systemic activity, dose equivalence and relative therapeutic index for fluticasone furoate (FF), fluticasone propionate (FP) and budesonide (BUD) in asthmatic subjects.
Source: International Congress 2019 – New towards old therapies in airway diseases
Year: 2019



Does fluticasone propionate (FP) improve pulmonary function in asthmatic infants?
Source: Eur Respir J 2003; 22: Suppl. 45, 495s
Year: 2003

The effects of treatment with fluticasone propionate alone and combination with salmeterol on asthma control and airway inflammation
Source: Eur Respir J 2003; 22: Suppl. 45, 287s
Year: 2003

Dose-related effect of inhaled fluticasone on allergen-induced airway changes in rats
Source: Eur Respir J 2002; 20: 873-879
Year: 2002



Initiation of treatment with the salmeterol/fluticasone propionate (FP) combination product is better than inhaled steroid alone (FP) in asthmatic patients symptomatic on short-acting bronchodilator alone
Source: Eur Respir J 2003; 22: Suppl. 45, 410s
Year: 2003

The effect of fluticasone vs fluticasone plus salmeterol on allergen-induced bronchial inflammation in asthmatic patients. A long-term RCT
Source: Eur Respir J 2004; 24: Suppl. 48, 125s
Year: 2004

Comparison of fluticasone propionate + salmeterol (FP+S) and montelukast (MK) on bronchial reactivity (BR), pulmonary function (PF) and clinical outcome in children with mild asthma
Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues
Year: 2009


Fluticasone furoate (FF), an inhaled corticosteroid (ICS), demonstrates efficacy in asthma patients symptomatic on moderate doses of ICS therapy
Source: Annual Congress 2010 - New treatments for asthma and COPD
Year: 2010

Effect of the addition of montelukast to inhaled fluticasone propionate on immunopathology in bronchial biopsies from mild to moderate asthmatics
Source: Eur Respir J 2002; 20: Suppl. 38, 388s
Year: 2002

Airway and systemic effects of hydrofluoroalkane formulations of high dose ciclesonide and fluticasone propionate in moderate persistent asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 583s
Year: 2004

Salmeterol/fluticasone combination product (SFC) provides better asthma control compared to high dose fluticasone (FP) in symptomatic patients with asthma
Source: Annual Congress 2005 - Combination therapy for asthma. Which, why and how?
Year: 2005


Is low dose inhaled fluticasone propionate safe in young children with asthma?
Source: Annual Congress 2008 - Preschool wheezing: advances in diagnosis, phenotyping and therapy
Year: 2008


Adrenal suppression from high-dose inhaled fluticasone propionate in children with asthma
Source: Eur Respir J 2003; 21: 633-636
Year: 2003